½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1467690

¸»ÃÊÇ÷°ü ±â±â ½ÃÀå º¸°í¼­ : ±â±â À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Peripheral Vascular Devices Market Report by Device Type, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 138 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¸»ÃÊÇ÷°ü ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 116¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2024-2032³â »çÀÌ 5.9%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸À̸ç 2032³â±îÁö 198¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

¸»ÃÊÇ÷°üÁúȯ(PVD)Àº ½ÉÀåÀ̳ª ³ú ¿ÜºÎÀÇ Ç÷°üÀÌ Á¼¾ÆÁö°Å³ª ¸·È÷°Å³ª °æ·ÃÀ» ÀÏÀ¸ÄÑ ¹ß»ýÇÏ´Â ¼øȯÀå¾Ö¸¦ ¸»ÇÕ´Ï´Ù. ÀÌ·± ÀÏÀÌ ¹ß»ýÇϸé Ç÷°üÀ» ÅëÇÑ Ç÷¾×ÀÇ È帧ÀÌ ³ªºüÁ® ¾àÁ¡, ÅëÁõ, ±«Àú, ´Ù¸® Å»¸ð, ¹«°¨°¢, ±ÙÀ°ÀÇ ¹«°Å¿ò µîÀÇ Áõ»óÀÌ ³ªÅ¸³³´Ï´Ù. Ç÷°ü Çü¼º Ä«Å×ÅÍ, ¸»ÃÊ °¡À̵å¿ÍÀ̾î, ´ëÁ¤¸Æ ÇÊÅÍ, ½ºÅÙÆ® À̽Ä, »öÀü ¹æÁö ÀåÄ¡(EPD)¿Í °°Àº ¸»ÃÊÇ÷°ü ±â±¸´Â µ¿¸ÆÀÇ ¸·Èû°ú ÇùÂøÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¸·ÈûÀº ƯÈ÷ ¸»ÃÊÇ÷°ü°è¿¡¼­ ¹ß°ßµÇ´Â ÇöóÅ© ÃàÀû¿¡ ÀÇÇØ ¹ß»ýÇÏ¿© Ç÷°üÀ» Á¦ÇÑÇÏ°í ½Åü ºÎÀ§·ÎÀÇ Ç÷·ù¸¦ °¨¼Ò½Ãŵ´Ï´Ù. ¸»ÃÊÇ÷°ü±â±¸´Â ¾ÈÀüÇÏ°í °¨¿°°ú ¿°ÁõÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ°í Ç÷·ù¸¦ °³¼±ÇÏ¸ç µ¿¸ÆÀ» ÅëÇØ »ê¼Ò°¡ ÇÔÀ¯ µÈ Ç÷¾×À» °ø±ÞÇÕ´Ï´Ù.

¸»ÃÊÇ÷°ü ±â±â ½ÃÀå µ¿Çâ:

Àü ¼¼°èÀûÀ¸·Î Á¤¸Æ Áúȯ ¶Ç´Â CVI(¸¸¼ºÁ¤¸ÆºÎÀü)ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå Àü¸ÁÀÌ ¹à¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸»ÃÊÇ÷°ü ±â±â´Â ³ú, ´Ù¸®, ´Ù¸®¿¡ ÃæºÐÇÑ Ç÷·ù¸¦ °ø±ÞÇÏ¿© ÀûÀýÇÑ ±â´ÉÀ» ¼öÇàÇϵµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í ¸»Ãʵ¿¸ÆÁúȯ(PAD) ¹× Æó»ö°ú °°Àº ´Ù¾çÇÑ ÁúȯÀÇ ¹ß»ý·ü Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ´Â Èí¿¬°ú °úÀ½, ¿îµ¿ ºÎÁ·, °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü µî »ýÈ° ½À°üÀÇ º¯È­·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ¿Í´Â º°µµ·Î, ÇÕº´Áõ °¨¼Ò, ¼ö¼ú ÈÄ ÅëÁõ °¨¼Ò, ÀÔ¿ø ±â°£ ´ÜÃà, ºü¸¥ ȸº¹ µîÀ¸·Î ÀÎÇØ ÃÖ¼Òħ½À¼ö¼ú(MIS)¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ź·ÂÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á׻󵿸ưæÈ­Áõ, ºñ¸¸, »ýÈ°½À°üº´ÀÇ Áõ°¡¿¡ µû¸¥ Á׻󵿸ÆÀýÁ¦¼ú ÀåºñÀÇ º¸±ÞÀÌ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÇ·á »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ¼ÒºñÀÚÀÇ ÁöÃâ ´É·Â Áõ°¡, ±¤¹üÀ§ÇÑ ¿¬±¸ °³¹ß(R&D) È°µ¿ µî ´Ù¸¥ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé

  • 2023³â ¼¼°è ¸»ÃÊÇ÷°ü ±â±â ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¸»ÃÊÇ÷°ü ±â±â ¼¼°è ½ÃÀå ¼ºÀå·ü Àü¸ÁÀº?
  • ¸»ÃÊÇ÷°ü ±â±â ¼¼°è ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • COVID-19°¡ Àü ¼¼°è ¸»ÃÊÇ÷°ü ±â±â ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ±â±â À¯Çüº° ¸»ÃÊÇ÷°ü ±â±â ¼¼°è ½ÃÀå ÇöȲÀº?
  • ¸»ÃÊÇ÷°ü ±â±â ¼¼°è ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ºÐ·ù´Â?
  • ¸»ÃÊÇ÷°ü ±â±â ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¸»ÃÊÇ÷°ü ±â±â ¼¼°è ½ÃÀå ÁÖ¿ä ÁøÃâ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¸»ÃÊÇ÷°ü ±â±â ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ±â±â À¯Çüº°

  • ¸»ÃÊÇ÷°ü¿ë ½ºÅÙÆ®
  • ¸»ÃÊ°æ°ü Ç÷°ü¼ºÇü¼ú(PTA)¿ë dz¼± Ä«Å×ÅÍ
  • ¸»ÃÊÇ÷°ü¼ºÇü¼ú(PTA)¿ë °¡À̵å¿ÍÀ̾î
  • ¾ÆÅ×·ºÅä¹Ì ±â±â
  • »öÀü¹æÁö ±â±â
  • ÇÏ´ëÁ¤¸Æ ÇÊÅÍ
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø¡¤Å¬¸®´Ð
  • ¿Ü·¡ ÀÇ·á ¼¾ÅÍ
  • Àü¹® Ŭ¸®´Ð
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï »óȲ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • B. Braun SE(B. Braun Holding GmbH & Co. KG)
    • Becton, Dickinson and Company
    • Biotronik SE & Co. KG
    • Boston Scientific Corporation
    • Cook Group Incorporated
    • Cordis Corporation
    • iVascular S.L.U.
    • Koninklijke Philips N.V.
    • Medtronic plc
    • Terumo Medical Corporation
ksm 24.05.03

The global peripheral vascular devices market size reached US$ 11.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 19.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032.

Peripheral vascular disease (PVD) is a circulatory condition caused due to the narrowing, blockage, or spasms in the blood vessels located outside the heart and brain. Such occurrences reduce the blood flow through the vessels, resulting in weakness, pain, gangrene, hair loss on the legs, numbness, and muscle heaviness. Peripheral vascular devices, such as angioplasty catheters, peripheral guidewires, vena cava filters, stent grafts, and embolic protection devices (EPD), are used to treat artery blockages and narrowing. These blockages, particularly found in the peripheral vasculature, are caused by plaque build-up, which limits the blood vessels and reduces blood flow to the body parts. Peripheral vascular devices are safe, minimize the risk of infection and irritation, improve blood flow, and supply oxygenated blood through arteries.

Peripheral Vascular Devices Market Trends:

The increasing prevalence of venous diseases or CVI (chronic venous insufficiency) across the globe is creating a positive outlook for the market. Peripheral vascular devices provide sufficient blood flow to the brain, legs, and feet for proper functioning. Additionally, the rising geriatric population and the increasing incidences of various ailments, such as peripheral artery disease (PAD) and blockages, are favoring the market growth. Furthermore, this can be attributed to changing lifestyle habits, including smoking and high alcohol consumption, coupled with physical inactivity and unhealthy dietary habits. Apart from this, the growing inclination toward minimally invasive surgeries (MIS) due to fewer complications, less postoperative pain, shortened hospital stay, and faster recovery times are providing an impetus to the market growth. Moreover, the widespread adoption of atherectomy devices owing to the increasing prevalence of atherosclerosis, obesity, and lifestyle-related disorders is positively influencing the market growth. Other factors, including the significant growth in the healthcare industry, rising expenditure capacities of consumers, and extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global peripheral vascular devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on device type and end user.

Breakup by Device Type:

Peripheral Vascular Stents

Peripheral Transluminal Angioplasty (PTA) Balloon Catheters

Peripheral Transluminal Angioplasty (PTA) Guidewires

Atherectomy Devices

Embolic Protection Devices

Inferior Vena Cava Filters

Others

Breakup by End User:

Hospitals and Clinics

Ambulatory Care Centers

Specialty Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun SE (B. Braun Holding GmbH & Co. KG), Becton, Dickinson and Company, Biotronik SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Cordis Corporation, iVascular S.L.U., Koninklijke Philips N.V., Medtronic plc and Terumo Medical Corporation.

Key Questions Answered in This Report

  • 1. What was the size of the global peripheral vascular devices market in 2023?
  • 2. What is the expected growth rate of the global peripheral vascular devices market during 2024-2032?
  • 3. What are the key factors driving the global peripheral vascular devices market?
  • 4. What has been the impact of COVID-19 on the global peripheral vascular devices market?
  • 5. What is the breakup of the global peripheral vascular devices market based on the device type?
  • 6. What is the breakup of the global peripheral vascular devices market based on the end user?
  • 7. What are the key regions in the global peripheral vascular devices market?
  • 8. Who are the key players/companies in the global peripheral vascular devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Peripheral Vascular Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Device Type

  • 6.1 Peripheral Vascular Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Peripheral Transluminal Angioplasty (PTA) Balloon Catheters
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Peripheral Transluminal Angioplasty (PTA) Guidewires
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Atherectomy Devices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Embolic Protection Devices
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Inferior Vena Cava Filters
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals and Clinics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ambulatory Care Centers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Specialty Clinics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 B. Braun SE (B. Braun Holding GmbH & Co. KG)
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 SWOT Analysis
    • 13.3.3 Becton, Dickinson and Company
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Biotronik SE & Co. KG
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 SWOT Analysis
    • 13.3.5 Boston Scientific Corporation
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Cook Group Incorporated
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Cordis Corporation
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 iVascular S.L.U.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Koninklijke Philips N.V.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Medtronic plc
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Terumo Medical Corporation
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦